Urology resident publication output and its relationship to future academic achievement.

PubWeight™: 1.85‹?› | Rank: Top 3%

🔗 View Article (PMC 3565588)

Published in J Urol on December 18, 2010

Authors

Glen Yang1, Uwais B Zaid, Bradley A Erickson, Sarah D Blaschko, Peter R Carroll, Benjamin N Breyer

Author Affiliations

1: Department of Urology, University of California-San Francisco, San Francisco, California 94143, USA.

Articles by these authors

Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09

National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81

Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol (2004) 4.66

Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol (2005) 4.40

Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04

Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92

The changing face of prostate cancer. J Clin Oncol (2005) 3.84

Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57

Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26

Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18

Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14

Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93

Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93

Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89

Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88

Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84

Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84

Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83

The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70

Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69

Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65

Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55

Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55

Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol (2007) 2.39

Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39

Stricture recurrence after urethroplasty: a systematic review. J Urol (2009) 2.34

NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31

The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29

De novo erectile dysfunction after anterior urethroplasty: a systematic review and meta-analysis. BJU Int (2013) 2.27

Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol (2004) 2.23

Urethroplasty with abdominal skin grafts for long segment urethral strictures. J Urol (2010) 2.19

Urethroplasty after radiation therapy for prostate cancer. Urology (2012) 2.11

Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08

Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05

Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04

Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol (2008) 2.02

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01

Improving access to urologic care for rural populations through outreach clinics. Urology (2013) 2.01

Increased risk of high-grade prostate cancer among infertile men. Cancer (2010) 2.00

Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98

Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93

The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91

Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology (2002) 1.90

Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med (2003) 1.89

Use of Google Insights for Search to track seasonal and geographic kidney stone incidence in the United States. Urology (2011) 1.84

High-risk prostate cancer in the United States, 1990-2007. World J Urol (2008) 1.83

Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81

Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80

Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77

Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol (2007) 1.70

Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol (2010) 1.70

Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology (2004) 1.69

Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology (2002) 1.68

Staged reconstruction of long segment urethral strictures in men with previous pediatric hypospadias repair. J Urol (2008) 1.68

Pediatric genitourinary injuries in the United States from 2002 to 2010. J Urol (2012) 1.65

Associations among hypospadias, cryptorchidism, anogenital distance, and endocrine disruption. Curr Urol Rep (2008) 1.62

How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int (2013) 1.61

Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A (2008) 1.61

Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer. Cancer (2010) 1.60

Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology (2013) 1.59

Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer (2006) 1.58

Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology (2004) 1.58

The quantitative Gleason score improves prostate cancer risk assessment. Cancer (2012) 1.57

Cumulative cost pattern comparison of prostate cancer treatments. Cancer (2007) 1.57

Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57

The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol (2012) 1.56

Treatment of adults with complications from previous hypospadias surgery. J Urol (2012) 1.55

Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol (2013) 1.55

Socioeconomic, anthropomorphic, and demographic predictors of adult sexual activity in the United States: data from the national survey of family growth. J Sex Med (2009) 1.54

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54

Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52

Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol (2005) 1.52

Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. BJU Int (2010) 1.52

Impact of increased number of biopsies on the nature of prostate cancer identified. J Urol (2006) 1.50

Men with low preoperative sexual function may benefit from nerve sparing radical prostatectomy. J Urol (2013) 1.49

The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol (2009) 1.49

Treatment trends for stage I renal cell carcinoma. J Urol (2011) 1.47

Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46

Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? J Urol (2005) 1.46

Modifying urology residency training: time to speed up or slow down? J Urol (2006) 1.44

Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42

Oncological and functional outcomes of radical cystectomy and orthotopic bladder replacement in women. Urology (2011) 1.39